摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4,6,7,8,9-hexahydro-2-methyl-3-oxo-2H-naphtho[2,3-e]-1,2-thiazine-4-carboxylic acid ethylester 1,1-dioxide | 869733-84-6

中文名称
——
中文别名
——
英文名称
3,4,6,7,8,9-hexahydro-2-methyl-3-oxo-2H-naphtho[2,3-e]-1,2-thiazine-4-carboxylic acid ethylester 1,1-dioxide
英文别名
ethyl 2-methyl-1,1,3-trioxo-6,7,8,9-tetrahydro-4H-benzo[g][1,2]benzothiazine-4-carboxylate
3,4,6,7,8,9-hexahydro-2-methyl-3-oxo-2H-naphtho[2,3-e]-1,2-thiazine-4-carboxylic acid ethylester 1,1-dioxide化学式
CAS
869733-84-6
化学式
C16H19NO5S
mdl
——
分子量
337.397
InChiKey
JFDLWRWFGBQDFW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    89.1
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
    申请人:Bornemann Klaus
    公开号:US20050277635A1
    公开(公告)日:2005-12-15
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R 2 , R 3 , R 5 , R 6 , L1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)异构体平增加、Aβ异构体平比例改变和/或含有Aβ肽的斑块形成有关的疾病或病症的方法,包括向该哺乳动物投与公式Ia、Ib中选定的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i的定义如权利要求1所述。
  • Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds
    申请人:BORNEMANN Klaus
    公开号:US20090099159A1
    公开(公告)日:2009-04-16
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R 2 , R 3 , R 5 , R 6 , L 1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)的同工异构体平增加和/或Aβ同工异构体平比例改变和/或含有Aβ同工异构体的斑块形成相关的疾病或病症的方法,包括向该哺乳动物施用从Ia、Ib公式中选择的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i如权利要求1中所定义。
  • US7375220B2
    申请人:——
    公开号:US7375220B2
    公开(公告)日:2008-05-20
  • US7393843B2
    申请人:——
    公开号:US7393843B2
    公开(公告)日:2008-07-01
  • US7534787B2
    申请人:——
    公开号:US7534787B2
    公开(公告)日:2009-05-19
查看更多

同类化合物

硫杂环庚烷-2-酮 硫杂环庚烷 环己硫醚 桉叶硫醚 四氢-6-硫代-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3-酮 二氢-7-丁基-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 二氢-1,4-二甲基-1,4-乙桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 二氢-1,4-乙基桥-1H,3H-噻吩并(3,4-c)噻吩-3,6(4H)-二酮 β.-D-半乳吡喃糖,1,6-二脱氧-1,6-环硫- 6-硫杂双环[3.2.1]辛烷 6-甲基-7-硫杂二环[4.1.0]庚烷 5-氧代噻吩-3-羧酸甲酯 5-氧代-4-噻吩甲酸乙酯 4,7,7-三甲基-6-硫代二环[3.2.1]辛烷 3-硫杂二环[3.2.1]辛烷-2-酮,1,8,8-三甲基-,(1R)- 3-甲基噻吩1,1-二氧化物 3-(4-甲基苯基)噻吩1,1-二氧化物 2-羟基噻烷 1-癸基2-[[1-(2-氯-5-磺基苯基)-4,5-二氢-3-甲基-5-羰基-1H-吡唑-4-基]偶氮]苯酸酯 1,6:4,5-二去氢-2,3-二脱氧-1-硫代己糖醇 (1S,4S,5S)-4,7,7-三甲基-6-硫代二环[3.2.4]辛烷 (-)-2,10-(3,3二氯樟脑)磺内酰胺 hexahydro-2,5-methano-thiopyrano[3,2-b]furan 4,4-dioxide (3aR,6R,6aR)-2,2-Dimethyl-4-(2-methyl-[1,3]dithian-2-yl)-6-(tetrahydro-pyran-2-yloxymethyl)-tetrahydro-furo[3,4-d][1,3]dioxol-4-ol trans-4,5-Dihydroxythiocane 3,4-dichloro-3-methyl-tetrahydro-thiophene 1,3-di-O-acetyl-2,5-anhydro-4-O-methyl-6-thio-α-D-glucoseptanose DL-(1,5/4)-4,7-O-benzylidene-5-C-hydroxymethyl-1,4-cyclohexanediol (1R,5S)-9-Thia-tricyclo[3.3.1.02,4]nonane 9,9-dioxide (1R,2R,5R,6S,9S,10S)-12-thiatetracyclo[8.3.0.02,5.06,9]tridecane Perhydro-bis-pyrano<2.3-b:3'.2'-e>-1,4-oxathian torilensulfat 2-acetoxy-1,5-dithiacyclooctane 1,2,4,6-Tetrakis-trifluoromethyl-3,5,7-trithia-tricyclo[4.1.0.02,4]heptane (2R,4R,6R)-4-Chloro-6-(1,2-dichloro-ethyl)-4-methyl-[1,2]oxathiane 2-oxide 2-[1,3,5]Trithian-2-yl-cyclohexanol trans-(RuCl2(S(CH2)3CH2)4) 4,6,7,7-tetramethyl-2-thia-bicyclo(2.2.2)oct-5-ene 2,2-dioxide (1R,5R)-9-Oxa-3,7-dithia-tricyclo[3.3.1.02,4]nonane 3,3,7,7-tetraoxide Dodecahydro-thianthren-tetroxyd {Rh2Cl2(μ-CO)(bis(ethylthio)methane)2} 2-(8β-hydroxy-1β-methyl-7β,2α,6α-tricyclo<5.4.0.02,6>undecyl)1,3-dithiane 17β-Hydroxymethyl-estra-4,8(14)-dien-3,3-ethylendithioketal (9'S,10'S,13'R,17'S)-17'-(4,4-dimethyl-3-methylenepentyl)-9',10',13'-trimethyl-1',2',6',7',9',10',11',12',13',15',16',17'-dodecahydrospiro[cyclopentane-1,3'-cyclopenta[a]phenanthrene] 1,2,3,4,5,6,7,8,8a,10a-Decahydro-9,10-dithiaphenanthren Acetic acid (3R,4S,5S,6R)-5-acetoxy-3,6-dimethoxy-thiepan-4-yl ester 3,4-Di-sec.-butoxysulfolan 1,8,15,22,29,36-hexathia-cyclodotetracontane (3aS,7aR)-3a,7a-Dimethyl-1,3,3a,4,7,7a-hexahydro-benzo[c]thiophene